Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
New York Hospital Queens · Orlando Immunology Center · +12 more institutions
Indexed incrossrefpubmed
Abstract
Background
Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that showed substantial antiviral activity in a phase 1b study.
Methods
copies per milliliter in the viral load by day 15; a key secondary end point was a viral load of less than 50 copies per milliliter at week 26.
Citation impact
289
total citations
- FWCI
- 25.60
- Percentile
- 100%
- References
- 11
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Capsid
- Multiple drug resistance
- Virology
- Human immunodeficiency virus (HIV)
- Biology
- Virus
- Drug resistance
- Medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.